TriSalus Life Sciences Inc.(TLSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TLSI TriSalus Life Sciences Inc.

Pre-Mkt 12-19 04:21:55 EST

7.28

-0.02

-0.27%

High7.53	Low7.11	Vol161.48K
Open7.37	D1 Closing7.30	Amplitude5.75%
Mkt Cap363.74M	Tradable Cap287.46M	Total Shares49.96M
T/O1.19M	T/O Rate0.41%	Tradable Shares39.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TLSI","market":"US","secType":"STK","nameCN":"TriSalus Life Sciences Inc.","latestPrice":7.28,"timestamp":1766091600000,"preClose":7.3,"halted":0,"volume":161475,"delay":0,"floatShares":39485900,"shares":49964311,"eps":-2.144093,"marketStatus":"Pre-Mkt","change":-0.02,"latestTime":"12-19 04:21:55 EST","open":7.37,"high":7.53,"low":7.1101,"amount":1185651.948516,"amplitude":0.057521,"askPrice":7.74,"askSize":50,"bidPrice":2.92,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.144093,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766154600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":7.28,"postHourTrading":{"tag":"盘后","latestPrice":7.28,"preClose":7.28,"latestTime":"16:10 EST","volume":6201,"amount":45143.28,"timestamp":1766092204637},"volumeRatio":0.9246777733402712},"requestUrl":"/m/hq/s/TLSI/tweets","defaultTab":"tweets","newsList":[{"id":"2592948645","title":"TriSalus Life Sciences Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2592948645","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592948645?lang=en_us&edition=fundamental","pubTime":"2025-12-18 04:18","pubTimestamp":1766002680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TLSI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 15:18 ET (20:18 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSI","BK4139"],"gpt_icon":0},{"id":"2589883200","title":"TriSalus Life Sciences Hosts Virtual KOL Event on TriNav Infusion System for Symptomatic Thyroid Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2589883200","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589883200?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:01","pubTimestamp":1764882072,"startTime":"0","endTime":"0","summary":"TriSalus Life Sciences Inc. will host a virtual key opinion leader  event on December 15, 2025, at 2:00 PM ET to discuss the TriNav Infusion System for the treatment of symptomatic thyroid disease. The event will feature Dr. Juan C. Camacho of Florida State University, an expert in image-guided thyroid therapies, who will join company management to address the unmet needs and current treatment landscape for thyroid disease. A question and answer session will follow the presentations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire  on December 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4ls5WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSI","BK4139"],"gpt_icon":0},{"id":"2584955344","title":"TriSalus Life Sciences Launches New Drug Delivery System","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955344","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584955344?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:25","pubTimestamp":1763475924,"startTime":"0","endTime":"0","summary":"TriSalus Life Sciences  said Tuesday it is launching the TriNav XP, a pressure-enabled drug delivery system designed to improve therapy delivery in different vascular environments.The TriNav XP is engineered specifically for compatibility with larger embolic particles -- beads up to and including 700 micrometers, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4127","LU0651946864.USD","LU1051768304.USD","LU0788109048.HKD","LU1861217088.USD","BK4585","LU0047713382.USD","LU1861220207.SGD","TLSI","LU0572108347.SGD","LU1051769294.HKD","XP","LU0072463663.USD","LU1515016050.SGD","LU0651947912.USD"],"gpt_icon":0},{"id":"2584937081","title":"BRIEF-Trisalus Life Sciences Launches Trinav® Xp Infusion System To Expand Options For Pressure-Enabled Drug Delivery™","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937081","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937081?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:09","pubTimestamp":1763471357,"startTime":"0","endTime":"0","summary":"BRIEF-Trisalus Life Sciences Launches Trinav Xp Infusion System To Expand Options For Pressure-Enabled Drug DeliveryTriSalus Life Sciences Inc TLSI.O:TRISALUS LIFE SCIENCES LAUNCHES TRINAV XP INFUSION","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA85BNY9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Trisalus Life Sciences Launches Trinav® Xp Infusion System To Expand Options For Pressure-Enabled Drug Delivery™","news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSI"],"gpt_icon":0},{"id":"2584937521","title":"TriSalus Life Sciences Launches Trinav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937521","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937521?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:00","pubTimestamp":1763470800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUA85BNY9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSI"],"gpt_icon":0},{"id":"2583651517","title":"BRIEF-TriSalus Life Sciences Files For Mixed Shelf Of Up To $150 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651517","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583651517?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:42","pubTimestamp":1763070153,"startTime":"0","endTime":"0","summary":"BRIEF-TriSalus Life Sciences Files For Mixed Shelf Of Up To $150 Million - SEC FilingNov 13  - TriSalus Life Sciences Inc TLSI.O:TRISALUS LIFE SCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILINGSource text: [ID:n0001493152-25-022367]Further company coverage: TLSI.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP2E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSI","BK4139"],"gpt_icon":0},{"id":"2583517507","title":"TriSalus Life Sciences Inc Files for Mixed Shelf of up to $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583517507","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583517507?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:41","pubTimestamp":1763070087,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP2E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSI","BK4139"],"gpt_icon":0},{"id":"2583151119","title":"TriSalus Life Sciences reports third quarter revenue of $11.6 million, up 57% year-over-year","url":"https://stock-news.laohu8.com/highlight/detail?id=2583151119","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583151119?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:02","pubTimestamp":1763067730,"startTime":"0","endTime":"0","summary":"Trisalus Life Sciences Inc. reported third quarter 2025 net sales of $11.6 million, representing a 57% increase year-over-year and a 3% sequential rise from the previous quarter. Adjusted EBITDA losses were $5.4 million, compared to $7.2 million in the same period of 2024. Cash and cash equivalents as of September 30, 2025, totaled $22.7 million. The company lowered its quarterly cash burn by approximately 50% quarter-over-quarter and reaffirmed its 2025 revenue guidance of at least 50% growth. Business developments included expanding the use of TriNav in liver embolization and simplifying the capital structure through the completion of an exchange offering for Series A Preferred stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL3vM0MF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSI"],"gpt_icon":0},{"id":"2583511105","title":"TriSalus Life Sciences Q3 EPS $(0.96) Misses $(0.15) Estimate, Sales $11.566M Miss $11.760M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511105","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511105?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:02","pubTimestamp":1763067722,"startTime":"0","endTime":"0","summary":"TriSalus Life Sciences Q3 EPS $(0.96) Misses $(0.15) Estimate, Sales $11.566M Miss $11.760M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48849638/trisalus-life-sciences-q3-eps-0-96-misses-0-15-estimate-sales-11-566m-miss-11-760m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"TriSalus Life Sciences Q3 EPS $(0.96) Misses $(0.15) Estimate, Sales $11.566M Miss $11.760M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSI"],"gpt_icon":0},{"id":"2583635514","title":"TriSalus Life Sciences Q3 EPS USD -0.96","url":"https://stock-news.laohu8.com/highlight/detail?id=2583635514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583635514?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX863F71:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSI","BK4139"],"gpt_icon":0},{"id":"2583511945","title":"TriSalus Life Sciences Q3 Pretax Profit USD -10.806 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511945?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX863F71:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSI","BK4139"],"gpt_icon":0},{"id":"2583511486","title":"Press Release: TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511486","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511486?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:01","pubTimestamp":1763067660,"startTime":"0","endTime":"0","summary":"TriSalus Reports $11.6 million in Revenue, Up 57% Year-over-Year, Reflecting Strong Liver Embolization growth. Investigator Published Data Show TriNav Enables Safe, Effective Thyroid Embolization Alternative to Surgery. Reaffirmed revenue guidance of at least 50% growth due to continued commercial momentum. Hosting Conference Call and Webcast today at 4:30pm ET. TriSalus Life Sciences, Inc.  , an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and provides an operation update.--  Generated $11.6 million in net sales, a 57% increase year-over-year,and sequential growth of 3% over the second quarter 2025.--  Lowered quarterly cash burn by approximately 50% quarter-over-quarter.--  Delivered strong commercial performance, with expanding use of. TriNav in liver embolization, and c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4604","TM","BK4588","BK4022","03160","BK4139","TLSI","BK4555","BK4585","BK4099","BK4232"],"gpt_icon":0},{"id":"2582397930","title":"Trisalus Life Sciences to Present at Piper Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2582397930","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582397930?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:05","pubTimestamp":1762895136,"startTime":"0","endTime":"0","summary":"Trisalus Life Sciences Inc. will participate in the 37th Annual Piper Healthcare Conference in New York, NY, on December 2. Management will hold one-on-one meetings and present a corporate overview at 3:10 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire  on November 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL2WR7R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSI"],"gpt_icon":0},{"id":"2582797378","title":"TriSalus Life Sciences Hosts Virtual KOL Event on TriNav Infusion System for Uterine Fibroids","url":"https://stock-news.laohu8.com/highlight/detail?id=2582797378","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582797378?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:04","pubTimestamp":1762779858,"startTime":"0","endTime":"0","summary":"Trisalus Life Sciences Inc. will host a virtual key opinion leader event on November 12, 2025, to discuss the TriNav Infusion System for the treatment of uterine fibroids. The event will feature an overview of the TriNav Infusion System's pressure-enabled drug delivery approach and review the uterine artery embolization market landscape.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL3WTlj2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSI","BK4139"],"gpt_icon":0},{"id":"2579714689","title":"Trisalus Life Sciences Inc. to Release Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579714689","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579714689?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:01","pubTimestamp":1761825670,"startTime":"0","endTime":"0","summary":"TriSalus Life Sciences Inc. will announce its third quarter 2025 financial results on November 13, 2025. The results will be released prior to a conference call and webcast scheduled for 4:30 PM eastern time. The event will be webcast live on the investor relations section of TriSalus' website, and a replay will be available following the event. Parties interested in participating by phone should register using this online form.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire  on October 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLbkgkvB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSI"],"gpt_icon":0},{"id":"2572557463","title":"TriSalus Life Sciences Announces Resignation of Board Member Sean Murphy","url":"https://stock-news.laohu8.com/highlight/detail?id=2572557463","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572557463?lang=en_us&edition=fundamental","pubTime":"2025-10-02 04:29","pubTimestamp":1759350572,"startTime":"0","endTime":"0","summary":"Trisalus Life Sciences Inc. announced that Sean Murphy has resigned from his position as a member of the Board of Directors and the Science and Technology Committee, effective immediately. The company stated that his departure was not due to any disagreement regarding company operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL9zqw5R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSI"],"gpt_icon":0},{"id":"2563071018","title":"TriSalus Life Sciences Inc. Increases CFO David Patience's Salary to $550,000 and Grants Stock Options Tied to $75 Million Revenue Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2563071018","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563071018?lang=en_us&edition=fundamental","pubTime":"2025-08-30 04:15","pubTimestamp":1756498544,"startTime":"0","endTime":"0","summary":"TriSalus Life Sciences Inc. Increases CFO David Patience's Salary to $550,000 and Grants Stock Options Tied to $75 Million Revenue Milestone. TriSalus Life Sciences Inc. has announced an increase in the annual compensation of its Chief Financial Officer, Mr. David Patience. Effective immediately, Mr. Patience's base salary has been raised from $450,000 to $550,000. Additionally, the company has granted him stock options to purchase 249,899 shares of common stock at an exercise price of $5.11 per share. These options will vest once the company achieves or exceeds $75 million in revenue over any twelve consecutive months before the end of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the origi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL1sSGnK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSI"],"gpt_icon":0},{"id":"2559696621","title":"TriSalus Life Sciences Inc. Unveils Investor Presentation Highlighting Innovations in Drug Delivery for Solid Tumors and Market Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2559696621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559696621?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:15","pubTimestamp":1755029751,"startTime":"0","endTime":"0","summary":"TriSalus Life Sciences Inc. Unveils Investor Presentation Highlighting Innovations in Drug Delivery for Solid Tumors and Market Opportunities. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDLbDgVyK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSI","BK4139"],"gpt_icon":0},{"id":"2559462997","title":"TriSalus Life Sciences Reports 52% Revenue Growth in Q2 2025; Net Loss Increases to $9M, EPS at $0.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2559462997","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559462997?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:02","pubTimestamp":1755028922,"startTime":"0","endTime":"0","summary":"Trisalus Life Sciences Inc.  has reported its financial results for the second quarter ended June 30, 2025, showing a revenue of $11.2 million, which marks a 52% increase compared to the same period in 2024 and a 22% growth quarter-over-quarter. This revenue growth was primarily driven by enhanced selling resources and increased market share of the TriNav system. Despite this growth, the company experienced a net loss attributable to common stockholders of $9.0 million, up from a $5.1 million net loss in the same period of the previous year. The increase in net loss is primarily attributed to non-cash adjustments related to the fair value of a contingent earnout liability. The company has confirmed its revenue guidance, projecting at least 50% growth due to sustained commercial momentum. Additionally, Trisalus Life Sciences has simplified its capital structure through an exchange offering of Series A Preferred stock and is positioned with $26.5 million in cash and cash equivalents as o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL7y4sW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSI"],"gpt_icon":0},{"id":"2559629955","title":"TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2559629955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559629955?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:01","pubTimestamp":1755028861,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUA5R419W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSI","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trisaluslifesci.com","stockEarnings":[{"period":"1week","weight":-0.0293},{"period":"1month","weight":0.5826},{"period":"3month","weight":0.4857},{"period":"6month","weight":0.3023},{"period":"1year","weight":0.9362},{"period":"ytd","weight":0.4531}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.023435},{"month":2,"riseRate":1,"avgChangeRate":0.048907},{"month":3,"riseRate":0.4,"avgChangeRate":-0.017625},{"month":4,"riseRate":0.4,"avgChangeRate":-0.020255},{"month":5,"riseRate":0.2,"avgChangeRate":-0.048777},{"month":6,"riseRate":0.6,"avgChangeRate":-0.025956},{"month":7,"riseRate":0.6,"avgChangeRate":-0.051263},{"month":8,"riseRate":0.6,"avgChangeRate":-0.031956},{"month":9,"riseRate":0.4,"avgChangeRate":-0.086929},{"month":10,"riseRate":0.6,"avgChangeRate":-0.054113},{"month":11,"riseRate":0.8,"avgChangeRate":0.107245},{"month":12,"riseRate":0.6,"avgChangeRate":0.251771}],"exchange":"NASDAQ","name":"TriSalus Life Sciences Inc.","nameEN":"TriSalus Life Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TriSalus Life Sciences Inc.(TLSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TriSalus Life Sciences Inc.(TLSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TriSalus Life Sciences Inc.,TLSI,TriSalus Life Sciences Inc.股票,TriSalus Life Sciences Inc.股票老虎,TriSalus Life Sciences Inc.股票老虎国际,TriSalus Life Sciences Inc.行情,TriSalus Life Sciences Inc.股票行情,TriSalus Life Sciences Inc.股价,TriSalus Life Sciences Inc.股市,TriSalus Life Sciences Inc.股票价格,TriSalus Life Sciences Inc.股票交易,TriSalus Life Sciences Inc.股票购买,TriSalus Life Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TriSalus Life Sciences Inc.(TLSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TriSalus Life Sciences Inc.(TLSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction